Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Feindor

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Toxins|September 26, 2021
Venom Immunotherapy: From Proteins to Product to Patient ProtectionMartin Feindor, Matthew D Heath, Simon J Hewings, et al.
Plos One|December 1, 2017
First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgeryNorbert Pfeiffer, Bogomil Voykov, Giulia Renieri, et al.
The World Allergy Organization Journal|January 6, 2026
Patient preference in allergen immunotherapy - Understanding the patient's viewSven Becker, Martin Feindor, Anke Graessel, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Toxins|September 26, 2021
Venom Immunotherapy: From Proteins to Product to Patient ProtectionMartin Feindor, Matthew D Heath, Simon J Hewings, et al.
Plos One|December 1, 2017
First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgeryNorbert Pfeiffer, Bogomil Voykov, Giulia Renieri, et al.
The World Allergy Organization Journal|January 6, 2026
Patient preference in allergen immunotherapy - Understanding the patient's viewSven Becker, Martin Feindor, Anke Graessel, et al.
Pageof 1